CureVac - Hauptforum Forum: Community User: NeulingImDAX

@candis Welche zusätzlichen Erkenntnisse lassen sich aus diesem alten Artikel ziehen?

https://www.businessinsider.de/wissenschaft/gesundheit/corona-impfstoff-curevac-rechnet-anfang-juni-mit-eu-zulassung-c/

Wieso sollte ntv was wissen...

SF is very professional - she stick rigidly to the regulations- you may talk to her and ask her questions -she will only give answers that she is permitted . On manufacturing at Curevac own risk in February . My assessment " Curvac are fortunate to have SF

Das sind gute News👍

Ruudi. Claudia must receive information ? From Someone https://twitter.com/Landfunk/status/1391637292457119746/photo/1

Sie würde auch nie inoffizielle Aussagen, wem immer gegenüber auch treffen.

Nein.

@rudi... Du kennst sie persönlich?

Fluffi?

Nein, ich kenne das Interview noch nicht. Aber Sarah hat mir bereits Mitte März das clinical trial protocol der HERALD-Studie ans Herz gelegt. Die Lektüre hat sich für mich gelohnt.

Curevac hat die Freigabe ntv News 21:15 h

Das bedeutet: "We'll have the only study that will offer real-world data on the current distribution of variants," said Sarah Fakih, the firm's head of investor relations. https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-says-well-track-request-vaccine-approval-planned-2021-05-05/

Es gibt m.E. keine klinischen Studien gegen die Mutanten, jedoch einige kleinere Gruppen/Auswertungen mit stark schwankenden Aussagen bzgl. der efficacay von BioNTech gegen B1.351. Eine Studie aus Texas spricht nur von ca. 14% Schutz gegen Infektion. Es gibt aber auch andere Studien. Grundsätzlich ist zudem genau zu unterscheiden, welcher „Schutz“ gemeint ist. Infektion oder Hospitalisierung? Nur exemplarisch hier eine Studie aus Qatar: https://www.nejm.org/doi/full/10.1056/NEJMc2104974?query=recirc_mostViewed_railB_article Für D ist aktuell B1.17 relevant. Da ist BioNTech gut aufgestellt. Allerdings wird man aktuell die indische Variante (B1.617) genauer untersuchen müssen.

Sounds good

"Translated from Mexico EL Faninanciero " CureVac (which was tested in Mexico) advances in Phase III and promises to be better than Pfizer and Moderna vaccines The German drug would be easier to distribute and store compared to other vaccines that use messenger RNA technology. May 06, 2021 | {CureVac prepares 'super vaccine' against COVID strains} Faced with the multiple shortages of vaccines worldwide and the hoarding of doses in the United States, the German pharmaceutical company CureVac announced this Thursday that it is close to presenting the results of its Phase III clinical trial of its COVID-19 vaccine.... It should be said that, as part of the clinical tests, this vaccine arrived in Mexico at the end of January to be applied to more than 8,000 volunteers.... The Teutonic firm, whose headquarters are in the city of Tübingen, Germany, explained that its drug could have multiple advantages over that of the pharmaceutical giants, since it would not require the use of large ultra-cold freezers for storage and transportation. At the beginning of the pandemic, Pfizer-BioNTech and Moderna were the first pharmaceutical companies to develop vaccines with messenger RNA technology; Both were shown to have very high efficacy and safety rates, which is why the WHO and other world bodies authorized their use.... {Unfortunately the access, transport, hoarding and storage of these vaccines has been an obstacle to curb the number of infections and deaths per day; so the German company will release the results of the last trial phase to begin its distribution around the world}.... "The German biotechnology firm CureVac believes that the European Union could approve its vaccine against covid-19 at the end of May or June," revealed Thorsten Schueller, spokesman for the pharmaceutical company, to the German newspaper Augsburger Allgemeine ... Schueller added that they are well advanced in stage three clinical trials and only awaiting final data for approval. He also stressed that they continue to plan to produce up to 300 million doses this year, once they have the results.... “According to experts”, {CureVac has a significant advantage over Pfizer-BioNTech and Moderna vaccines, which must be kept in a freezer with very cold temperatures; while the German drug is stable in a refrigerator, which makes it easier to transport and store}..... For biologist “Ingmar Hoerr, co-founder of CureVac”, the COVID-19 vaccine is the result of more than 25 years of experimentation and work with RNA, which makes it highly effective compared to Pfizer, Moderna and AstraZeneca.... “Most importantly”, {many scientists have claimed that the drugmaker discovered and used a form of RNA that could remain stable at room temperatures. Instead of requiring a freezer, the CureVac vaccine could be refrigerated}.... At the start of the pandemic, CureVac, BioNTech and Moderna teamed up to make RNA vaccines. However, BioNTech partnered with Pfizer, while Moderna worked hand in hand with various national institutes of health, receiving one billion dollars from the US government; so CureVac lagged behind.... Despite this, the German government decided to invest 300 million euros in June, and in December, the pharmaceutical company began phase III, recruiting 40,000 volunteers in Europe and Latin America....